Hematology CME

  • FEATURED
    FREE GIFT CARD

    BoardVitals Hematology and Oncology CME Pro Plus w/ Bonus $2,500 Amazon or Visa Prepaid Card

    Complete your CME and MOC Requirements Online with the BoardVitals Online CME + MOC Hematology/Oncology Self-Assessment Activity with up to a bonus $2,500 Amazon or Visa Prepaid Card. Answer board-style questions and cases related to your specialty and earn credits fast!

    Key features of BoardVitals Online CME + MOC Self-Assessment Activity include:

    • Thousands of board-style questions and cases with evidence based explanations for review
    • Aligned with the MOC / Recertification exam content for your specialty board
    • Answer questions to earn credits and correct wrong answers as you go
    • Earn up to 100 AMA PRA Category 1 CreditsTM and MOC credits (varies by specialty)
    • Up to 24-month access + a bonus $2,500 Amazon or Visa Prepaid Card (your choice.)

    Target Audience: Physicians specializing in Hematology or Oncology.

    See full details chevron_right
    • Cost: Varies
    • Credit hours: 27
    • CME credits awarded by: University of Nebraska Medical Center
    • Format: On-Demand Online
    • Material last updated: Continuously Updated
  • FEATURED
    FREE GIFT CARD

    MDCalc CME With Free $2,250 Gift Card

    Maximize your CME allowance with MDCalc and get up to a $2,250 bonus gift card of your choice. Earn AMA PRA Category 1 CreditsTM for clinical content on 150+ calculators across multiple medical specialties. Easily earn and redeem CME at the point-of-care, online on our website or mobile app. Over 1 million medical professionals use MDCalc’s 550+ tools daily to support clinical decision making at the bedside.

    See full details chevron_right
    • Cost: Varies
    • Credit hours: 50+
    • CME credits awarded by: EBMedicine
    • Format: On-Demand Online
    • Material last updated: Continuously Updated
  • FEATURED

    BoardVitals Hematology and Oncology CME Board Review

    The BoardVitals Hematology and Oncology CME Review offers clinicians 27 AMA PRA Category 1 CreditsTM, 27 ABIM MOC points, and over 500 Hematology and Oncology board review questions. The questions cover key topics including Breast Cancer, Gynecologic Cancer, and Transfusion Medicine. This question bank will assist clinicians with Hematology and Oncology certification and recertification.

    The BoardVitals Hematology and Oncology CME Review also features:

    • Quick and Convenient CME
    • Computer, phone, and tablet access
    • Constantly updated up-to-date questions
    • Questions that are targeted specifically to the exam
    • Online CME tracker
    • 100% Pass Guarantee
    • Statistical comparison to other Hematology and Oncology test-takers (Nationally)

     

    After completing this activity, you should be able to:

    • Make a diagnosis
    • Order and interpret results
    • Assess risk, determine prognosis, and apply principles from epidemiologic studies
    • Describe the underlying pathophysiology of disease and basic science knowledge

     

    Target Audience: Hematologists and Oncologists

    See full details chevron_right
    • Cost: $599
    • Credit hours: 27
    • CME credits awarded by: BoardVitals
    • Format: On-Demand Online
    • Material last updated: Continuously Updated
  • 15% OFF / CODE: CME15
    FEATURED

    The Brigham and Dana-Farber Board Review in Hematology

    Learn from the experts and prep for your hematology board exam with this comprehensive audio/video program. Ideal for MOC.

    Topics covered in this Hematology CME program include:
    • Molecular Genetics of Cancer
    • Infections in Cancer Patients
    • Symptom Management in Patients with Cancer
    • Acute Leukemias 
    • Sickle Cell Disease 
    • Hemophilia

    After completing this course, physicians will be able to:
    • Apply current/recommended hematology guidelines in clinical practice
    • Perform differential diagnosis of complex hematologic disorders
    • Identify and apply current therapeutic options for hematologic disorders
    • Evaluate and interpret up-to-date literature relevant to hematology
    • Illustrate knowledge of pathophysiology of hematology disorders
    • Apply knowledge gained to the ABIM certification/recertification

    Target Audience: Hematology fellows/trainees, Hematologists/Oncologists and Internists

    See full details chevron_right
    • Cost: $1295
    • Credit hours: 26
    • CME credits awarded by: Oakstone Publishing, LLC
    • Format: On-Demand Online, Online Video, Online Audio, Audio CD
    • Material last updated: June 30, 2018
    • Expiration of CME credit: June 30, 2021
  • MedCram 3 year All Access CME Pass

    Medical videos & lectures explained clearly by world-class instructors.

    Memorable illustrations, clinical scenarios, and passionate instructors set MedCram apart from other online medical lectures.

    We prioritize the most important clinically relevant and practical information for clinical practice.

    Understanding medicine has never been so simplified.

    See full details chevron_right
    • Cost: $495
    • Credit hours: 46.75
    • CME credits awarded by: ACCME
    • Format: Medical education videos available on demand
    • Material last updated: Continuously Updated
  • FREE

    Treating Oncology Patients During COVID-19

    Activity Description / Statement of Need: The COVID-19 pandemic has led to unprecedented changes in health care delivery worldwide, affecting the way that nearly every medical specialty can safely practice. As with other fields of medicine, oncology has its own challenges in navigating the pandemic. Based on pre-pandemic estimates, 1.8 million new cancer diagnoses would be expected in 2020, equating to approximately 5,000 new cancer diagnoses per day. Evidence thus far suggests that COVID-19 is associated with significantly more complications and a higher risk of death in patients with cancer or with a history of cancer. Furthermore, patients with cancer have also been shown to have a higher COVID-19 infection rate than the general population, suggesting increased susceptibility, potentially due to immunosuppression, comorbidities, or poor health status related to cancer or its treatment. Based on these data, oncology specialists are said to be fighting “a war on two fronts” by balancing the risks of COVID-19 transmission and acquisition with the risks of delayed cancer diagnosis and treatment. This represents an unmet need among oncology practitioners as they navigate this new health care landscape.

    Target Audience:

    Healthcare professionals, including medical oncologists; radiation oncologists; surgical oncologists; surgeons; radiologists; nuclear medicine specialists; nurse practitioners and physician assistants who practice in oncology; and other healthcare providers who manage cancer.

    By the end of the session the participant will be able to:

    • Recall the symptoms of COVID-19 infection and best practices for screening patients, health care providers, and staff in the oncology setting.
    • Develop a plan to provide oncology care in the setting of the COVID-19 pandemic.
    • Describe the risks of delaying cancer diagnosis and treatment against the risk of COVID-19 exposure and infection.
    • See full details chevron_right
    • Cost: Free
    • Credit hours: .75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 09/22/2020
    • Expiration of CME credit: 09/22/2022
  • FREE

    Congenital Thrombotic Thrombocytopenic Purpura (CTTP): Updates from the American Society of Hematology (ASH) 2019 annual meeting

    Thrombotic thrombocytopenic purpura (TTP) is a rare blood disorder that impacts three in a million adults per year, with congenital or hereditary TTP (cTTP, also known as Upshaw-Schulman syndrome) accounting for a third of the overall incidence. The incidence of TTP rises with increasing age and the mortality rate of untreated TTP may be as high as 90%.

    In recent years molecular mechanisms contributing to TTP have been identified: patients diagnosed with TTP have larger von Willebrand factor molecules (vWF) and a defective protease enzyme of A Disintegrinlike And Metalloprotease with ThromboSpondin type 1 motif 13 (ADAMTS13), which cleaves larger vWF molecules and inhibits platelet adhesion. In congenital or hereditary TTP (cTTP, also known as Upshaw-Schulman syndrome), the gene that codes of ADAMTS13 is defective and cannot properly produce the enzyme, whereas in acquired TTP, antibody production leads to downstream enzymatic deactivation.

    Target Audience:
    The following healthcare professionals: hematologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in hematology; and any other healthcare professionals with an interest in or who clinically encounter patients with cTTP.

    By the end of the session the participant will be able to:

    • Summarize the most impactful findings presented at the ASH 2019 annual meeting relating to congenital TTP
    • Recall the pathophysiology of congenital TTP
    • Describe the clinical manifestations and methods of establishing a diagnosis of cTTP, and apply that information to a patient case
    • List treatment strategies for cTTP, and apply that information to a patient case
    See full details chevron_right
    • Cost: Free
    • Credit hours: .75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 08/30/2020
    • Expiration of CME credit: 08/30/2022
  • FREE

    Hemophilia B: Optimizing Pharmacotherapeutic Management Strategies

    Hemophilia is a genetic disease caused by mutation of one of the genes for coagulation proteins leading to dangerous, uncontrolled bleeding. In hemophilia B, a mutation in the gene for factor IX (FIX) leads to an endogenous deficiency in the clotting factor. The incidence of hemophilia B is the same in all geographic regions, populations, and ethnic groups,affecting approximately 1 out of every 30,000 male births. The condition is diagnosed by measuring FIX activity, and patients with severe hemophilia have levels of 1% or less.

    Patients with severe hemophilia B are at risk for spontaneous, life-threatening bleeding episodes. Untreated, the life expectancy is approximately 20 years,and painful or even life-threatening morbidities include intracranial hemorrhage, severe bleeding in other organ systems, musculoskeletal injury, and joint injury. In contrast, in people with moderate or mild hemophilia, abnormal bleeding usually occurs after minor trauma or surgery.

    Physical therapy can ease symptoms if internal bleeding has damaged a patient’s joints, and surgery may be necessary if internal bleeding has caused severe damage. However, the current standard of therapy for hemophilia B is intravenous infusion of therapeutic factor concentrates. Through the reduction in the number of bleeding incidences and improvement in quality of life, factor replacement therapy has significantly reduced the morbidity and mortality of hemophilia. Furthermore, prophylactic therapy has the demonstrated benefit of reducing the development of hemophilic arthropathy.

    Target Audience:

    The following healthcare professionals: hematology, primary care physicians, and pediatricians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in hematology as well as other Hemophilia Treatment Center HCPs; and any other clinicians with an interest in hemophilia B.

    By the end of the session the participant will be able to:

    • Describe the risk factors and occurrence of hemophilia B.
    • Identify available prophylactic and treatment options for hemophilia B and apply them to a patient case.
    • Identify the new treatment options for hemophilia B.
    • Identify adherence barriers in and deliver effective treatment counseling to patients with hemophilia B.
    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 06/10/2020
    • Expiration of CME credit: 06/10/2022
  • FREE

    Hemophilia A: Optimizing Pharmacotherapeutic Management Strategies

    Hemophilia is a genetic disease caused by mutation of one of the genes for coagulation proteins leading to dangerous, uncontrolled bleeding. In hemophilia A, a mutation in the gene for factor VIII (FVIII) leads to an endogenous deficiency in the clotting factor. The incidence of hemophilia A is the same in all geographic regions, populations, and ethnic groups, affecting approximately 1 out of every 5000 male births. The condition is diagnosed by measuring FVIII activity, and patients with severe hemophilia have FVIII activity of 1% or less. Patients with severe hemophilia A are at risk for spontaneous, life-threatening bleeding episodes. Untreated, the life expectancy is approximately 20 years, and painful or even life-threatening morbidities include intracranial hemorrhage, severe bleeding in other organ systems, musculoskeletal injury, and joint injury. In contrast, in people with moderate or mild hemophilia, abnormal bleeding usually occurs after minor trauma or surgery.

    Target Audience:

    The following healthcare professionals: hematology, primary care physicians, and pediatricians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in hematology as well as other Hemophilia Treatment Center HCPs; and any other clinicians with an interest in hemophilia A.

    By the end of the session the participant will be able to:

    • Describe the risk factors and occurrence of hemophilia A.
    • Identify available prophylactic and treatment options for hemophilia A and apply them to a patient case.
    • Identify the new treatment options for hemophilia A.
    • Identify adherence barriers in and deliver effective treatment counseling to patients with hemophilia A.
    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 06/06/2020
    • Expiration of CME credit: 06/06/2022
  • FREE

    Hemophilia B: Updates from 2018 American Society of Hematology Annual Meeting (ASH 2018)

    Hemophilia is a genetic disease caused by mutation of one of the genes for coagulation proteins leading to dangerous, uncontrolled bleeding. In hemophilia B, a mutation in the gene for factor IX (FIX) leads to an endogenous deficiency in the clotting factor

    After completing Hemophilia B: Updates from 2018 American Society of Hematology Annual Meeting (ASH 2018) physicians will better be able to:

    • Describe the gene therapy and its anticipated impact on hemophilia B therapy
    • List evidence-supported benefits of switching to extended half-life / dose-interval clotting factors and apply that knowledge to patient cases
    • Summarize the most impactful findings presented at ASH 2018 meeting relating to prophylactic and therapeutic agents to treat hemophilia B, and apply** them to patient cases
    • Describe how immune modulation therapy may be used to induce immune tolerance to Factor IX inhibitors

    Target Audience: hematologists; primary care physicians, physician assistants, nurse practitioners, nurses, and pharmacists who practice in hematology; and any other healthcare professionals with an interest in or who clinically encounter patients with hemophilia B.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 0.75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: March 05, 2019
    • Expiration of CME credit: March 05, 2021